Fulcrum Therapeutics (NASDAQ:FULC) Releases Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) posted its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10), FiscalAI reports.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC traded down $0.06 during mid-day trading on Thursday, reaching $3.68. 2,139,086 shares of the company’s stock were exchanged, compared to its average volume of 1,591,154. Fulcrum Therapeutics has a 52 week low of $2.83 and a 52 week high of $15.74. The firm has a 50-day moving average price of $3.74 and a two-hundred day moving average price of $5.62. The firm has a market capitalization of $281.09 million, a price-to-earnings ratio of -3.04 and a beta of 2.82.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $8.20.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.